These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 25510273)

  • 1. Novel immunotherapies for hematologic malignancies.
    Nelson MH; Paulos CM
    Immunol Rev; 2015 Jan; 263(1):90-105. PubMed ID: 25510273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic approaches for hematologic malignancies.
    Caligiuri MA; Velardi A; Scheinberg DA; Borrello IM
    Hematology Am Soc Hematol Educ Program; 2004; ():337-53. PubMed ID: 15561691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in hematologic malignancies: past, present, and future.
    Im A; Pavletic SZ
    J Hematol Oncol; 2017 Apr; 10(1):94. PubMed ID: 28434396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cell therapy to target hematologic malignancies.
    Kenderian SS; Ruella M; Gill S; Kalos M
    Cancer Res; 2014 Nov; 74(22):6383-9. PubMed ID: 25371415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
    Tsirigotis P; Shimoni A; Nagler A
    Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Modulation in Hematologic Malignancies.
    Dhodapkar MV; Dhodapkar KM
    Semin Oncol; 2015 Aug; 42(4):617-25. PubMed ID: 26320065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for combining immunotherapy with radiation for anticancer therapy.
    Seyedin SN; Schoenhals JE; Lee DA; Cortez MA; Wang X; Niknam S; Tang C; Hong DS; Naing A; Sharma P; Allison JP; Chang JY; Gomez DR; Heymach JV; Komaki RU; Cooper LJ; Welsh JW
    Immunotherapy; 2015; 7(9):967-980. PubMed ID: 26310908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.
    Klener P; Etrych T; Klener P
    Curr Med Chem; 2019; 26(6):1002-1018. PubMed ID: 28990505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
    Yoon DH; Osborn MJ; Tolar J; Kim CJ
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.
    Perales MA; Sauter CS; Armand P
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):17-22. PubMed ID: 26485445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
    Sun C; Dotti G; Savoldo B
    Blood; 2016 Jun; 127(26):3350-9. PubMed ID: 27207792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
    Yaguchi T; Kawakami Y
    Int Immunol; 2016 Aug; 28(8):393-9. PubMed ID: 27401477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematologic Malignancies: Plasma Cell Disorders.
    Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
    Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
    Gill S; June CH
    Immunol Rev; 2015 Jan; 263(1):68-89. PubMed ID: 25510272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
    Suzuki M; Curran KJ; Cheung NK
    Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recombinant Monoclonal Antibodies, from Tumor Targeting to Cancer Immunotherapy: A Critical Overview].
    Mach JP
    Mol Biol (Mosk); 2017; 51(6):1024-1038. PubMed ID: 29271965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
    Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
    Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.